New research reveals that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight much more quickly than those who halt traditional diet and exercise plans.
Published data in a prominent health publication shows that while overweight individuals frequently drop a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using these treatments must be aware of the risk of quick rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight in about a year and a half.
Analyzing Therapies
The study, which reviewed 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
The team note that people who shed pounds through diet and exercise typically have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Doctors propose the way of the jabs is key to understanding the accelerated rebound.
The injections copy a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Health authorities suggest the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, considering the significant potential of relapse, the therapy should be considered life-long.
This opinion is reinforced by drug manufacturers, who say that the findings "emphasize the persistent nature of excess weight," akin to managing diseases like diabetes.
User Experiences
Individuals who have discontinued the jabs describe a intense resurgence of cravings.
"I experienced a trigger that goes on and you become starving," recalled one woman.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while these medications are potent agents for weight loss, they are not a permanent solution and maintained weight loss hinges on combined behavioural management.
